My take is cardio protection, if proven, should be universal regardless of FTO expression level.
FTO suppression doesn't require it to be over expressed to prove bisantrene inhibits FTO so the trial should be ok on that front. The critical factor will be any increase in anti-cancer benefit. Some level of benefit across "all comers" would be great however increased or 'stunning' benefit results for those with FTO overexpressed would be highly encouraging. At least from a precision oncology point of view.
Ann: Updated Strategy and Investor Presentation, page-174
-
- There are more pages in this discussion • 335 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
